Detailed Information on Publication Record

PAGANO, Livio, Jon SALMANTON-GARCIA, Francesco MARCHESI, Ola BLENNOW, da Silva Maria GOMES, Andreas GLENTHOJ, van Doesum JAAP, Yavuz M BILGIN, Alberto LOPEZ-GARCIA, Federico ITRI, Raquel Nunes RODRIGUES, Barbora WEINBERGEROVA, Francesca FARINA, Giulia DRAGONETTI, Caroline Berg VENEMYR, van Praet JENS, Ozren JAKSIC, Toni VALKOVIC, Iker FALCES-ROMERO, Sonia MARTIN-PEREZ, Moraima JIMENEZ, Julio DAVILA-VALLS, Martin SCHONLEIN, Emanuele AMMATUNA, Stef MEERS, Mario DELIA, Zlate STOJANOSKI, Anna NORDLANDER, Tobias LAHMER, Laszlo Imre PINCZES, Caterina BUQUICCHIO, Klara PIUKOVICS, Irati ORMAZABAL-VELEZ, Nicola FRACCHIOLLA, Michail SAMARKOS, Gustavo-Adolfo MENDEZ, Jose-Angel HERNANDEZ-RIVAS, Ildefonso ESPIGADO, Martin CERNAN, Verena PETZER, Sylvain LAMURE, di Blasi ROBERTA, de Almedia Joyce MARQUES, Michelina DARGENIO, Monika M BIERNAT, Mariarita SCIUME, de Ramon CRISTINA, de Jonge NICK, Josip BATINIC, Avinash AUJAYEB, Monia MARCHETTI, Guillemette FOUQUET, Noemi FERNANDEZ, Giovanni ZAMBROTTA, Maria Vittoria SACCHI, Anna GUIDETTI, Fatih DEMIRKAN, Lucia PREZIOSO, Zdeněk RÁČIL, Marcio NUCCI, Milos MLADENOVIC, Raphael LIEVIN, Michaela HANAKOVA, Stefanie GRAFE, Uluhan SILI, Marina MACHADO, Chiara CATTANEO, Tatjana ADZIC-VUKICEVIC, Luisa VERGA, Jorge LABRADOR, Laman RAHIMLI, Matteo BONANNI, Francesco PASSAMONTI, Antonio PAGLIUCA, Paolo CORRADINI, Martin HOENIGL, Philipp KOEHLER, Alessandro BUSCA and Oliver A CORNELY. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey. Blood. Washington DC, USA: American Society of Hematology, 2022, vol. 140, No 26, p. 2773-2787. ISSN 0006-4971. Available from: https://dx.doi.org/10.1182/blood.2022017257.

Other formats: BibTeX LaTeX RIS

@article{2262414,
   author = {Pagano, Livio and SalmantonandGarcia, Jon and Marchesi, Francesco and Blennow, Ola and Gomes, da Silva Maria and Glenthoj, Andreas and Jaap, van Doesum and Bilgin, Yavuz M and LopezandGarcia, Alberto and Itri, Federico and Rodrigues, Raquel Nunes and Weinbergerova, Barbora and Farina, Francesca and Dragonetti, Giulia and Venemyr, Caroline Berg and Jens, van Praet and Jaksic, Ozren and Valkovic, Toni and FalcesandRomero, Iker and MartinandPerez, Sonia and Jimenez, Moraima and DavilaandValls, Julio and Schonlein, Martin and Ammatuna, Emanuele and Meers, Stef and Delia, Mario and Stojanoski, Zlate and Nordlander, Anna and Lahmer, Tobias and Pinczes, Laszlo Imre and Buquicchio, Caterina and Piukovics, Klara and OrmazabalandVelez, Irati and Fracchiolla, Nicola and Samarkos, Michail and Mendez, GustavoandAdolfo and HernandezandRivas, JoseandAngel and Espigado, Ildefonso and Cernan, Martin and Petzer, Verena and Lamure, Sylvain and Roberta, di Blasi and Marques, de Almedia Joyce and Dargenio, Michelina and Biernat, Monika M and Sciume, Mariarita and Cristina, de Ramon and Nick, de Jonge and Batinic, Josip and Aujayeb, Avinash and Marchetti, Monia and Fouquet, Guillemette and Fernandez, Noemi and Zambrotta, Giovanni and Sacchi, Maria Vittoria and Guidetti, Anna and Demirkan, Fatih and Prezioso, Lucia and Ráčil, Zdeněk and Nucci, Marcio and Mladenovic, Milos and Lievin, Raphael and Hanakova, Michaela and Grafe, Stefanie and Sili, Uluhan and Machado, Marina and Cattaneo, Chiara and AdzicandVukicevic, Tatjana and Verga, Luisa and Labrador, Jorge and Rahimli, Laman and Bonanni, Matteo and Passamonti, Francesco and Pagliuca, Antonio and Corradini, Paolo and Hoenigl, Martin and Koehler, Philipp and Busca, Alessandro and Cornely, Oliver A},
   article_location = {Washington DC, USA},
   article_number = {26},
   doi = {http://dx.doi.org/10.1182/blood.2022017257},
   keywords = {COVID-19; patients with hematologic malignancies},
   language = {eng},
   issn = {0006-4971},
   journal = {Blood},
   title = {Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey},
   url = {https://ashpublications.org/blood/article/140/26/2773/486672/Breakthrough-COVID-19-in-vaccinated-patients-with},
   volume = {140},
   year = {2022}
}

TY  - JOUR
ID  - 2262414
AU  - Pagano, Livio - Salmanton-Garcia, Jon - Marchesi, Francesco - Blennow, Ola - Gomes, da Silva Maria - Glenthoj, Andreas - Jaap, van Doesum - Bilgin, Yavuz M - Lopez-Garcia, Alberto - Itri, Federico - Rodrigues, Raquel Nunes - Weinbergerova, Barbora - Farina, Francesca - Dragonetti, Giulia - Venemyr, Caroline Berg - Jens, van Praet - Jaksic, Ozren - Valkovic, Toni - Falces-Romero, Iker - Martin-Perez, Sonia - Jimenez, Moraima - Davila-Valls, Julio - Schonlein, Martin - Ammatuna, Emanuele - Meers, Stef - Delia, Mario - Stojanoski, Zlate - Nordlander, Anna - Lahmer, Tobias - Pinczes, Laszlo Imre - Buquicchio, Caterina - Piukovics, Klara - Ormazabal-Velez, Irati - Fracchiolla, Nicola - Samarkos, Michail - Mendez, Gustavo-Adolfo - Hernandez-Rivas, Jose-Angel - Espigado, Ildefonso - Cernan, Martin - Petzer, Verena - Lamure, Sylvain - Roberta, di Blasi - Marques, de Almedia Joyce - Dargenio, Michelina - Biernat, Monika M - Sciume, Mariarita - Cristina, de Ramon - Nick, de Jonge - Batinic, Josip - Aujayeb, Avinash - Marchetti, Monia - Fouquet, Guillemette - Fernandez, Noemi - Zambrotta, Giovanni - Sacchi, Maria Vittoria - Guidetti, Anna - Demirkan, Fatih - Prezioso, Lucia - Ráčil, Zdeněk - Nucci, Marcio - Mladenovic, Milos - Lievin, Raphael - Hanakova, Michaela - Grafe, Stefanie - Sili, Uluhan - Machado, Marina - Cattaneo, Chiara - Adzic-Vukicevic, Tatjana - Verga, Luisa - Labrador, Jorge - Rahimli, Laman - Bonanni, Matteo - Passamonti, Francesco - Pagliuca, Antonio - Corradini, Paolo - Hoenigl, Martin - Koehler, Philipp - Busca, Alessandro - Cornely, Oliver A
PY  - 2022
TI  - Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
JF  - Blood
VL  - 140
IS  - 26
SP  - 2773-2787
EP  - 2773-2787
PB  - American Society of Hematology
SN  - 00064971
KW  - COVID-19
KW  - patients with hematologic malignancies
UR  - https://ashpublications.org/blood/article/140/26/2773/486672/Breakthrough-COVID-19-in-vaccinated-patients-with
N2  - Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccination. Adult patients with HM, >= 1 dose of anti-SARS-CoV-2 vaccine, and breakthrough COVID-19 between January 2021 and March 2022 were analyzed. A total of 1548 cases were included, mainly lymphoid malignancies (1181 cases, 76%). After viral sequencing in 753 cases (49%), the Omicron variant was prevalent (517, 68.7%). Most of the patients received <= 2 vaccine doses before COVID-19 (1419, 91%), mostly mRNAbased (1377, 89%). Overall, 906 patients (59%) received COVID-19-specific treatment. After 30-day follow-up from COVID-19 diagnosis, 143 patients (9%) died. The mortality rate in patients with the Omicron variant was 7.9%, comparable to other variants, with a significantly lower 30-day mortality rate than in the prevaccine era (31%). In the univariable analysis, older age (P <.001), active HM (P <.001), and severe and critical COVID-19 (P =.007 and P <.001, respectively) were associated with mortality. Conversely, patients receiving monoclonal antibodies, even for severe or critical COVID-19, had a lower mortality rate (P <.001). In the multivariable model, older age, active disease, critical COVID-19, and 2-3 comorbidities were correlated with a higher mortality, whereas monoclonal antibody administration, alone (P <.001) or combined with antivirals (P =.009), was protective. Although mortality is significantly lower than in the prevaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality. Death rate was lower in patients who received monoclonal antibodies, alone or in combination with antivirals.
ER  -

Basic information
Original name	Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Authors	PAGANO, Livio (guarantor), Jon SALMANTON-GARCIA, Francesco MARCHESI, Ola BLENNOW, da Silva Maria GOMES, Andreas GLENTHOJ, van Doesum JAAP, Yavuz M BILGIN, Alberto LOPEZ-GARCIA, Federico ITRI, Raquel Nunes RODRIGUES, Barbora WEINBERGEROVA, Francesca FARINA, Giulia DRAGONETTI, Caroline Berg VENEMYR, van Praet JENS, Ozren JAKSIC, Toni VALKOVIC, Iker FALCES-ROMERO, Sonia MARTIN-PEREZ, Moraima JIMENEZ, Julio DAVILA-VALLS, Martin SCHONLEIN, Emanuele AMMATUNA, Stef MEERS, Mario DELIA, Zlate STOJANOSKI, Anna NORDLANDER, Tobias LAHMER, Laszlo Imre PINCZES, Caterina BUQUICCHIO, Klara PIUKOVICS, Irati ORMAZABAL-VELEZ, Nicola FRACCHIOLLA, Michail SAMARKOS, Gustavo-Adolfo MENDEZ, Jose-Angel HERNANDEZ-RIVAS, Ildefonso ESPIGADO, Martin CERNAN, Verena PETZER, Sylvain LAMURE, di Blasi ROBERTA, de Almedia Joyce MARQUES, Michelina DARGENIO, Monika M BIERNAT, Mariarita SCIUME, de Ramon CRISTINA, de Jonge NICK, Josip BATINIC, Avinash AUJAYEB, Monia MARCHETTI, Guillemette FOUQUET, Noemi FERNANDEZ, Giovanni ZAMBROTTA, Maria Vittoria SACCHI, Anna GUIDETTI, Fatih DEMIRKAN, Lucia PREZIOSO, Zdeněk RÁČIL (203 Czech Republic, belonging to the institution), Marcio NUCCI, Milos MLADENOVIC, Raphael LIEVIN, Michaela HANAKOVA (203 Czech Republic), Stefanie GRAFE, Uluhan SILI, Marina MACHADO, Chiara CATTANEO, Tatjana ADZIC-VUKICEVIC, Luisa VERGA, Jorge LABRADOR, Laman RAHIMLI, Matteo BONANNI, Francesco PASSAMONTI, Antonio PAGLIUCA, Paolo CORRADINI, Martin HOENIGL, Philipp KOEHLER, Alessandro BUSCA and Oliver A CORNELY.
Edition	Blood, Washington DC, USA, American Society of Hematology, 2022, 0006-4971.

Other information
Original language	English
Type of outcome	Article in a journal
Field of Study	30205 Hematology
Country of publisher	United States of America
Confidentiality degree	is not subject to a state or trade secret
WWW	URL
Impact factor	Impact factor: 20.300
RIV identification code	RIV/00216224:14110/22:00128761
Organization unit	Faculty of Medicine
Doi	http://dx.doi.org/10.1182/blood.2022017257
UT WoS	000922296500001
Keywords in English	COVID-19; patients with hematologic malignancies
Tags	14110515, rivok
Tags	International impact, Reviewed
Changed by	Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 28/2/2023 14:52.

Abstract
Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccination. Adult patients with HM, >= 1 dose of anti-SARS-CoV-2 vaccine, and breakthrough COVID-19 between January 2021 and March 2022 were analyzed. A total of 1548 cases were included, mainly lymphoid malignancies (1181 cases, 76%). After viral sequencing in 753 cases (49%), the Omicron variant was prevalent (517, 68.7%). Most of the patients received <= 2 vaccine doses before COVID-19 (1419, 91%), mostly mRNAbased (1377, 89%). Overall, 906 patients (59%) received COVID-19-specific treatment. After 30-day follow-up from COVID-19 diagnosis, 143 patients (9%) died. The mortality rate in patients with the Omicron variant was 7.9%, comparable to other variants, with a significantly lower 30-day mortality rate than in the prevaccine era (31%). In the univariable analysis, older age (P <.001), active HM (P <.001), and severe and critical COVID-19 (P =.007 and P <.001, respectively) were associated with mortality. Conversely, patients receiving monoclonal antibodies, even for severe or critical COVID-19, had a lower mortality rate (P <.001). In the multivariable model, older age, active disease, critical COVID-19, and 2-3 comorbidities were correlated with a higher mortality, whereas monoclonal antibody administration, alone (P <.001) or combined with antivirals (P =.009), was protective. Although mortality is significantly lower than in the prevaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality. Death rate was lower in patients who received monoclonal antibodies, alone or in combination with antivirals.

Abstract

Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccination. Adult patients with HM, >= 1 dose of anti-SARS-CoV-2 vaccine, and breakthrough COVID-19 between January 2021 and March 2022 were analyzed. A total of 1548 cases were included, mainly lymphoid malignancies (1181 cases, 76%). After viral sequencing in 753 cases (49%), the Omicron variant was prevalent (517, 68.7%). Most of the patients received <= 2 vaccine doses before COVID-19 (1419, 91%), mostly mRNAbased (1377, 89%). Overall, 906 patients (59%) received COVID-19-specific treatment. After 30-day follow-up from COVID-19 diagnosis, 143 patients (9%) died. The mortality rate in patients with the Omicron variant was 7.9%, comparable to other variants, with a significantly lower 30-day mortality rate than in the prevaccine era (31%). In the univariable analysis, older age (P <.001), active HM (P <.001), and severe and critical COVID-19 (P =.007 and P <.001, respectively) were associated with mortality. Conversely, patients receiving monoclonal antibodies, even for severe or critical COVID-19, had a lower mortality rate (P <.001). In the multivariable model, older age, active disease, critical COVID-19, and 2-3 comorbidities were correlated with a higher mortality, whereas monoclonal antibody administration, alone (P <.001) or combined with antivirals (P =.009), was protective. Although mortality is significantly lower than in the prevaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality. Death rate was lower in patients who received monoclonal antibodies, alone or in combination with antivirals.